Effect of dapagliflozin combined with liraglutide in the treatment of patients with diabetic kidney disease and its influence on UAER,BUN and CⅣ levels
Objective To explore the clinical effect of dapagliflozin combined with liraglutide in the treatment of diabetic kidney disease(DKD).Methods A total of 86 patients with DKD admitted from January 2020 to December 2021 were included as the research objects.The patients were divided into group A(n=43)and group B(n=43)by random number table method.The group A was treated with liraglutide injection,and the group B was treated with dapagliflozin on the basis of the group A.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the group B was significantly higher than that in the group A(P＜0.05);there was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).After treatment,the levels of urinary albumin excretion rates(UAER),urinary albumin(UAlb)and blood urea nitrogen(BUN)in the two groups significantly decreased,and those in the group B were lower than the group A(P＜0.05).After treatment,the levels of collage type Ⅳ(CⅣ),cystatin C(Cys C)and tissue inhibitor of metalloproteinases-1(TIMP-1)in the two groups significantly decreased,and those in the group B were lower than the group A(P＜0.05).After treatment,the fasting plasma glucose(FPG),fasting insulin(FINS)levels and homeostasis model assessment for insulin resistance index(HOMA-IR)in the group B were lower than those in the group A(P＜0.05).Conclusion Dapagliflozin combined with liraglutide is effective in the treatment of DKD,which can promote the improvement of liver and kidney function.
NETL
NSTL
万方数据
